The HSDL1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical carcinoma cell line, engineered for targeted disruption of the HSDL1 gene. This product provides a heterogeneous pool of gene-edited cells, each carrying distinct CRISPR-mediated modifications at the HSDL1 locus, resulting in a functional loss-of-function model. Unlike clonal knockout cell lines, the polyclonal format circumvents clone-specific artifacts and offers a population-level representation of HSDL1 ablation, making it particularly suitable for studying genetic interactions and metabolic phenotypes in a diverse cellular context. The cells retain the intrinsic characteristics of the parental HeLa line while enabling researchers to interrogate the consequences of HSDL1 deficiency in cancer biology and lipid metabolism.
The host HeLa cell line is an immortalized epithelial cell model originally isolated from a cervical adenocarcinoma and remains positive for human papillomavirus type 18 (HPV18). These cells are widely employed in cancer research due to their robust growth, ease of manipulation, and well-characterized signaling networks. HeLa cells exhibit a high glycolytic rate and active lipid metabolism, providing a relevant backdrop for investigating the role of peroxisomal enzymes in tumor cell energetics. The cervical carcinoma origin also renders this line pertinent for studies of HPV-related oncogenesis and metabolic adaptation. The polyclonal knockout population generated from this background maintains the key oncogenic drivers while introducing a targeted genetic perturbation, enabling dissection of HSDL1 function without confounding clonal selection effects.
At the molecular level, HSDL1 encodes a putative peroxisomal short-chain dehydrogenase/reductase that is implicated in the ??-oxidation of fatty acids. The enzyme is regulated by several nuclear receptors and transcription factors, including PPAR??, which promotes fatty acid catabolism, SREBP1c, a master regulator of lipogenesis, and LXR, a cholesterol-responsive factor. HSDL1 functions downstream of these upstream regulators to modulate lipid metabolic flux. The protein is known to interact with core peroxisomal ??-oxidation enzymes such as ACOX1 (acyl-CoA oxidase 1), EHHADH (enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase), and HSD17B4 (17??-hydroxysteroid dehydrogenase type 4), forming a network that processes acyl-CoA thioesters into shorter-chain intermediates. Disruption of HSDL1 is predicted to perturb this enzymatic cascade, potentially leading to accumulation of ??-oxidation intermediates and alterations in lipid droplet dynamics. The pathway also includes CPT1A, which governs mitochondrial fatty acid import, highlighting the integration of peroxisomal and mitochondrial lipid handling. These molecular connections underscore the critical role of HSDL1 in maintaining cellular lipid homeostasis.
Within the HeLa cell context, ablation of HSDL1 is expected to compromise peroxisomal fatty acid oxidation, thereby shifting metabolic reliance toward alternative substrates and possibly inducing compensatory mechanisms. Such metabolic reprogramming can influence cancer cell proliferation, survival under nutrient stress, and redox balance. Given that HeLa cells are highly glycolytic, partial dependency on fatty acid oxidation for biosynthetic precursors or energy may reveal synthetic lethal vulnerabilities when HSDL1 is disrupted. This knockout model thus offers a powerful tool for dissecting the contribution of peroxisomal lipid metabolism to tumor aggressiveness and for identifying nodes of metabolic vulnerability that could be exploited therapeutically. The polyclonal nature of the knockout population ensures that a spectrum of gene-disruption efficiencies is represented, mimicking heterogeneous tumor environments and aiding in the assessment of penetrance for metabolic phenotypes.
Applications of the HSDL1 Knockout HeLa Polyclonal Cells span cancer metabolism research, fatty acid oxidation studies, and metabolic reprogramming investigations. Researchers can perform Western blotting and RT-qPCR to confirm HSDL1 protein depletion and transcript reduction in the polyclonal pool. Functional assays include fatty acid oxidation measurements using radiolabeled or fluorescent fatty acid tracers, metabolic flux analysis by mass spectrometry to trace lipid-derived carbon incorporation, and cell viability assays under conditions that challenge lipid metabolism (e.g., glucose deprivation or treatment with fatty acid oxidation inhibitors). These cells are also suitable for co-culture experiments and high-content screening aimed at identifying modifiers of HSDL1-dependent metabolic phenotypes. The polyclonal format provides a robust baseline for statistical analysis, as phenotypic variation within the population can be assessed. For further information on product validation or custom applications, please contact Ascent Research.
